Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China

Xiaopei Chao¹, Lei Li¹*, Ming Wu¹, Shuqing Ma¹, Xianjie Tan¹, Sen Zhong¹, Yalan Bi² and Jinghe Lang¹

Abstract
Background: The prevalence of Lynch syndrome and screening strategies for this disorder in Chinese patients with endometrial cancer have seldom been investigated. Such data would be essential for the screening, prevention, genetic counseling, and treatment of Lynch syndrome. The purpose of this prospective study was to determine the accuracy of the mismatch repair (MMR) protein immunohistochemistry (IHC), microsatellite instability (MSI) test, and clinical diagnostic criteria in screening for Lynch syndrome-associated endometrial cancer (LS-EC) in a prospective Chinese cohort.

Methods: All patients with newly diagnosed endometrial cancer (EC) were evaluated using clinical diagnostic criteria (Amsterdam II criteria and the revised Bethesda guidelines), MSI test, and IHC of MMR proteins in tumor tissues. For all patients, the screening results were compared with results of germline sequencing for pathogenic variants of MMR genes.

Results: Between December 2017 and August 2018, a total of 111 unselected patients with newly diagnosed EC were enrolled. Six patients (5.4%) harbored a pathogenic germline mutation of MMR genes: 1 had a mutation in MutL homolog 1 (MLH1), 2 in MutS homolog 2 (MSH2), and 3 in MutS homolog 6 (MSH6). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for identifying LS-EC were 33.3%, 88.6%, 14.3%, and 95.9% for the clinical criteria, 66.7%, 75.0%, 14.3%, and 97.3% for IHC of MMR proteins, 100%, 89.9%, 33.3%, and 100% for MSI test, and 95.9%, 72.4%, 20.0% and 100% for combined IHC and MSI test, respectively. The combination of IHC and MSI test had higher sensitivity and PPV than the clinical criteria (\( p = 0.030 \)). MSI test and IHC were highly concordant for LS-EC screening (73/77, 94.8%).

Conclusion: The accuracy of the combination of IHC of MMR proteins and MSI test for screening LS among Chinese patients with EC was superior to that of the clinical criteria.

Trial registration: NCT03291106. Registered on September 25, 2017

Keywords: Endometrial carcinoma, Lynch syndrome, Immunohistochemistry, Microsatellite instability, Germline mutations, DNA mismatch repair genes

*Correspondence: lireigh@163.com
¹ Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Shuaifuyuan No. 1, Dongcheng District, Beijing 100730, PR China
Full list of author information is available at the end of the article

© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Lynch syndrome (LS) is an autosomal-dominant, inherited, cancer susceptibility syndrome characterized by a high risk of malignancies, including colorectal (lifetime risk of 52–82%) [1], endometrial (lifetime risk of 25–60%) [2], and ovarian (lifetime risk of 4–12%) malignancies [3, 4]. The diagnosis of LS depends on the identification of germline mutations in the DNA mismatch repair (MMR) genes MutL homolog 1 (MLH1), MutS homolog 2 (MSH2), MutS homolog 6 (MSH6), PMS1 homolog 2 (PMS2), and/or epithelial cell adhesion molecule (EPCAM). The loss of DNA MMR leads to genomic instability by facilitating the accumulation of somatic mutations in various sequences. Endometrial cancer (EC) is the most common sentinel cancer in LS patients [5, 6]. Screening and diagnosing LS in EC patients is of great importance for affected individuals and their relatives, who would benefit from genetic counseling and enhanced surveillance [7, 8].

Screening strategies for LS-associated colorectal carcinomas have been studied thoroughly [9, 10]. However, screening for LS-associated EC (LS-EC) is controversial, as no consensus has been reached on the strategies, upper age threshold, or cost-effectiveness of screening [11, 12]. Historically, before the era of next-generation sequencing (NGS), LS screening methods have consisted of clinical diagnostic criteria based on individual and family cancer histories; these methods are relatively inexpensive. The most commonly used screening tools are the Amsterdam II clinical criteria [13] and the revised Bethesda guidelines [14]. However, the disadvantages of clinical criteria are the requirement for high accuracy in collecting individual and family histories and the actual low accuracy [15]. Furthermore, the traditional clinical schemas for LS screening are centered on the colon and have been shown to perform poorly at identifying LS in patients with gynecological malignancies [16]. In addition, these criteria are highly complex and poorly implemented in clinical practice. Therefore, the exploration of more efficient screening strategies for LS among EC patients is needed [17].

Universal molecular screening for LS in all newly diagnosed EC patients has been carried out in numerous centers in Europe [11] and the United States [12]. The National Comprehensive Cancer Network (NCCN) guidelines recommend that all patients with newly diagnosed EC be tested for loss of MMR function via immunohistochemical (IHC) and/or microsatellite instability (MSI) analysis independent of the clinical criteria [18]. This screening method is cost-effective and, at the same time, can ensure sensitivity and specificity [19, 20].

The Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) recommends IHC tissue screening for LS in type I and type II ECs among all patients below the age of 70 years and among all patients with endometrioid or clear cell ovarian cancers regardless of age [21]. However, there are few reports on the accuracy, strength, and limitations of these strategies when they are applied in Chinese EC patients. Identifying EC-related genetic factors would promote the development of genetic detection methods for carriers of potential EC-related mutations, potentially improving the health of women by establishing an innovative strategy for screening patients with hereditary carcinoma [22].

The objective of the present study was to determine the accuracy of IHC of MMR proteins, MSI test, and clinical criteria in screening for LS in a prospective cohort of Chinese EC patients. The results of screening were compared with those of universal germline sequencing for pathogenic variants of MMR genes.

Materials and methods
Ethics and registration
This study was an interim analysis for the project “Cohort Study of Universal Screening for Lynch Syndrome in Chinese Patients with Endometrial Cancer”, which was approved by the Institutional Review Board of Peking Union Medical College Hospital (Registration no. JS-1370). The registration number in clinicaltrials.gov is NCT03291106. The Chinese Human Genetic Resources Management Office of the National Ministry of Science and Technology has approved this study (Registration no. [2018] 522, http://www MOST.gov.cn/bszn/new/rlyc/jgcx/index.htm). The enrollment will end by the year 2020. All patients provided consent before enrollment.

Patient population
All patients newly diagnosed with EC since December 2017 in the Department of Obstetrics & Gynecology of the Peking Union Medical College Hospital were enrolled. Detailed epidemiological, clinical, and pathological data were prospectively collected. Patients with recurrent carcinoma and synchronous carcinomas were excluded.

Screening protocols
The screening protocols consisted of analysis of clinical criteria, IHC of MMR proteins, and MSI test, which were conducted for all patients if possible (Fig. 1). The costs of IHC of MMR proteins, MSI test, and germline sequencing have been reported by Peking Union Medical College Hospital to be 1000 RMB yuan (approximately 143 US dollars), 1500 RMB yuan (214 US dollars), and 3500 RMB yuan (500 US dollars) per patient, respectively. These costs will be covered by the Chinese Academy of Medical Sciences Initiative for Innovative Medicine.
Chao et al. Cancer Commun (2019) 39:42

(CAMS-2017-I2M-1-002) and the National Science-Technology Support Plan Projects (2015BAI13B04). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Peripheral blood samples were collected right before surgery, whereas bulky uterine tissues resected during hysterectomy were saved for IHC and MSI. No neoadjuvant therapy was administered in this study.

**Clinical criteria**

The patients’ family information was collected by two medical staff members, and their diseases were staged according to the International Federation of Gynecology and Obstetrics (FIGO) staging system. All patients’ records were evaluated according to the Amsterdam II clinical criteria [13] and the revised Bethesda guidelines [14]. Patients meeting either set of criteria were considered to have suspected LS-EC.

**IHC of MMR proteins**

IHC staining of proteins (MLH1, MSH2, MSH6, and PMS2) was performed on 4-µm-thick, formalin-fixed, paraffin-embedded sections of newly diagnosed EC tissues from these patients using a BenchMark ULTRA autostainer, version 12.3 (Ventana Medical Systems, New York, NY, USA) and the ready-to-use Ventana MMR IHC Panel with anti-MLH1 mouse monoclonal antibody (M1, 1:20 dilution), anti-MSH2 mouse monoclonal antibody (G219-1129, 1:100 dilution), anti-MSH6 rabbit monoclonal antibody (SP93, 1:1000 dilution), and anti-PMS2 mouse monoclonal antibody (A16-4, 1:100 dilution) from Roche Applied Science (New York, NY, USA) according to the manufacturer’s recommendations. Normal endometrial and/or myometrial tissues collected at least 3 cm away from the tumor margin were used as a normal control, and the results of IHC staining were examined by two independent pathologists. Intact IHC staining of MMR proteins was defined as positive staining of all MLH1, MSH2, MSH6, and PMS2 proteins, while deficient IHC staining was defined as negative staining of any of these four proteins. For deficient MLH1 expression, the methylation status of the MLH1 promoter was determined with methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) using the SALSA MS-MLPA Kit ME011-A1 (MRC-Holland, Amsterdam, the Netherlands) as reported by van Lier et al. [23].

**MSI test**

DNA was extracted from tumor tissues using a TIANamp FFPE DNA Kit (TIANGEN Co. Ltd., Beijing, China) according to the manufacturer's directions. A multiplex polymerase chain reaction (PCR)-capillary electrophoresis MSI detection kit (Sinomdgene Co. Ltd., Beijing, China) was used to perform microsatellite analysis of six mononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24, NR-27, and MONO-27) for MSI determination, one sex-determination marker (Amel site) and

---

**Fig. 1** A flow diagram of the study. IHC: immunohistochemistry; MMR: mismatch repair; MLH1: MutL homolog 1; PMS2: PMS1 homolog 2; MSH2: MutS homolog 2; MSH6: MutS homolog 6; MSI: microsatellite instability; MSI-H: high-frequency MSI; MSS: microsatellite stable.
two pentanucleotide repeat markers (Penta C and Penta D) for identification of the tumor tissues. An internal lane size standard (ROX-500) was added to the amplified samples to ensure accurate allele sizing. All other markers were amplified in 20 µL PCR resolution consisting of 10 µL Master Mix (SINOMdgene), 8 µL primer mixture (SINOMdgene), and 2 µL DNA. The PCR products were separated by capillary electrophoresis using an Applied Biosystems® 3130 or 3500 DX genetic analyzer (Los Angeles, CA, USA), and the output data were analyzed with the GeneMapper® software (Applied Biosystems) to determine the MSI status of the test samples. Panels and matched files were created to facilitate analysis using the GeneMapper® software. According to the recommendations of the National Cancer Institute [24], tumors with 2 or more of the tested markers to be instable were classified as high-frequency MSI (MSI-H); tumors with less than 2 of these markers to be instable, low-frequency MSI (MSI-L); and tumors without instability markers, microsatellite stable (MSS). MSI-H were designated MSI-positive, whereas MSI-L and MSS were designated MSI-negative.

Next-generation sequencing for germline mutation analysis

Germline mutation sequencing was performed for all patients. Genomic DNA was extracted from peripheral blood and quantified using a Qubit Instruments device (Life Technologies, Eugene, OR, USA). The extraction was assessed as unsuccessful when the total concentration of the extracted genomic DNA was lower than 25 ng. DNA fragmentation was evaluated by agarose gel electrophoresis. A TILLING PCR amplifier sequence (tPAS) library was constructed and quantified by qPCR. Then, the exons of the targeted genes—MLH1, MSH2, MSH6, PMS2, and EPCAM—were analyzed on the NextSeq CN500 platform (Hangzhou BerryGenomics Diagnostics Technology Co., Ltd, Hangzhou, Zhejiang, China), and the mutation types included single-nucleotide polymorphisms (SNPs) and insertion-deletions (indels). The data were analyzed using the Verita Trekker® Enliven® Genotypic Interpretation system (Berry Genomics Corporation, Beijing, China). The results for the sequence variants were classified according to the American College of Medical Genetics and Genomics (ACMG) guidelines [25]. If the results were interpreted to indicate a pathogenic/likely pathogenic mutation, the NGS data were confirmed by detecting the mutated gene via Sanger sequencing.

Statistical analyses

Statistical analyses were performed using the software SPSS, version 22.0 (SPSS Inc., Chicago, IL, USA). Normally distributed continuous variables were summarized as means and standard deviations (SDs), and non-normally distributed continuous variables were summarized as medians, ranges, and interquartile ranges. The t-test was used for continuous variables, and the Chi-squared test or Fisher’s exact test was used for categorical variables. Exact binomial 95% confidence intervals (CIs) were calculated to estimate sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of all screening methods. The McNemar test was used to compare sensitivity values. All analyses were two-tailed, and a p value of <0.05 was considered significant. MSI-H in combination with MMR protein-deficient and MSS in combination with MMR protein-intact were defined as concordance. Any other conditions were defined as disconcordance.

Results

Demographic data of the study population

Our study comprised of 112 patients with EC; 1 with pathologically identified primary cervical tumor was subsequently excluded. The demographic and clinico-pathological characteristics of the remaining 111 patients are shown in Table 1. The mean and median ages of the study cohort were 55.7 (SD, 9.7) years and 55 (range 31–82) years. Eighty-seven (78.4%) and 24 (21.6%) cases were type I and type II EC, respectively. According to the FIGO staging system, 87 (78.4%), 19 (17.1%), and 4 (3.6%) patients were in stage I, stage III, and stage IV, respectively, none had stage II disease. One patient refused retroperitoneal lymphadenectomy; therefore, the disease stage of that patient was unknown. Twenty-seven (24.3%) patients had involvement of the lower uterine segment.

Germline MMR mutation

All 111 patients had definitive germline mutation sequencing data. Among them, 14 (12.6%) had mutations of uncertain significance, 4 (3.6%) had likely pathogenic mutations, and 2 (1.8%) had pathogenic mutations (Table 2). Six (5.4%) patients were ultimately diagnosed with LS-EC with a mutation in one of the MMR genes: 1 in MLH1, 2 in MSH2, and 3 in MSH6. The cumulative cases of LS among the EC patients were 2 (6.3%), 6 (8.6%), and 6 (5.9%) before the ages of 50, 60, and 70, respectively. No patients >70 years of age had LS. Compared with patients harboring no MMR gene mutations, those with MMR gene mutations (LS) had lower BMI (p = 0.013), and the presence of MMR gene mutations was strongly associated with advanced lesions (p = 0.012) (Table 1).
Table 1 Demographic and clinicopathologic characteristics of the 111 unselected patients with endometrial cancer

| Characteristic                                      | Total (cases) | Germline MMR gene mutation | IHC MMR protein | MSI |
|----------------------------------------------------|---------------|-----------------------------|------------------|-----|
|                                                   |               | Absence | Presence | p value | Intact | Deficient | p value | Negative | Positive | p value |
| Total                                              | 111           | 105     | 6        | 0.440    | 74     | 28        | 0.102    | 71       | 12       | 0.658   |
| Age (years; median [range])                       | 56.00 (31–82) | 54.00 (48–57) | 0.374   | 56.50 (32–82) | 53.50 (31–73) | 0.437 | 2 (0–7) | 2 (0–5) | 0.020   |
| Gravidity [median (range)]                        | 2 (0–7)       | 2 (0–5) | 0.779    | 1 (0–4) | 1 (0–2) | 0.498    | 1 (0–4) | 1 (0–3) | 0.189   |
| Parity (median, range)                            | 1 (0–4)       | 1 (0–2) | 0.010    | 1 (0–4) | 1 (0–2) | 0.498    | 1 (0–4) | 1 (0–3) | 0.189   |
| Involvement of the lower uterine segment [cases (%)] | 27            | 24 (22.9) | 3 (50.0) | 0.132   | 17 (23.0) | 9 (32.1) | 0.343 | 14 (19.7) | 4 (33.3) | 0.290   |
| Type of EC [cases (%)]                            |               | 0.189 | 0.983 | 0.937   |
| Type I                                             | 87            | 81 (77.1) | 6 (100.0) | 58 (78.4) | 22 (78.6) | 54 (76.1) | 9 (75.0) | 0.354   |
| Type IIb                                          | 24            | 24 (22.9) | 0 (0)   | 16 (21.6) | 6 (21.4) | 17 (23.9) | 3 (25.0) | 0.354   |
| FIGO stage [cases (%)]b                           |               | 0.012 | 0.266 | 0.354   |
| FIGO I                                            | 87            | 85 (81.0) | 2 (33.3) | 61 (82.4) | 19 (67.9) | 60 (84.5) | 9 (75.0) | 0.354   |
| FIGO II                                           | 19            | 15 (14.3) | 4 (66.7) | 11 (14.9) | 8 (28.6) | 8 (11.3) | 3 (25.0) | 0.354   |
| FIGO IV                                           | 4             | 4 (3.8)   | 0 (0)   | 2 (2.7)  | 1 (3.6)  | 3 (4.2)  | 0 (0)   | 0 (0)    |
| Unknown                                           | 1             | 1 (1.0)   | 0 (0)   | 0 (0)    | 0 (0)    | 0 (0)    | 0 (0)    |

Italic values indicate significance of p value (p < 0.05)

MMR: mismatch repair; IHC: immunohistochemistry; MSI: microsatellite instability; SD: standard deviation; BMI: body mass index; EC: endometrial carcinoma; FIGO: International Federation of Gynecology and Obstetrics

a Among 24 cases of type II endometrial cancer, there were nine cases of the serous subtype, three of clear cell carcinoma, four of carcinosarcoma, one of undifferentiated carcinoma, and seven cases of mixed carcinoma (four cases of endometrioid and serous subtypes, two cases of endometrioid and clear cell carcinomas, two cases of endometrioid subtype and carcinosarcoma)

b No patients had FIGO II disease
Table 2 The results of germline mutation sequencing, IHC of MMR proteins, and MSI test for the 20 patients with MMR gene mutations

| Case no. | Germline MMR gene mutation* | Gene Transcript | Gene region | Nucleotide | Amino acid | Function change | Mutation type | IHC of MMR proteins | MSI | Amsterdam II criteria | Revised Bethesda guidelines |
|----------|----------------------------|----------------|-------------|------------|------------|----------------|---------------|-------------------|-----|---------------------|----------------------------|
| 1        | MSH6                      | NM_000179.2    | Exon 4      | c.C742T    | p.Arg248Ter | Nonsense      | Pathogenic    | (+) (+) (-) (+) | NA  | (-)                | (-)                        |
| 2        | MSH6                      | NM_000179.2    | Exon 4      | c.C3103T   | p.Arg1035Ter | Nonsense      | Pathogenic    | (+) (+) (+) (+) | MSH | (-)                | (-)                        |
| 3        | MSH2                      | NM_000251.2    | Exon 11     | c.1677_1680delAAAT | p.Asn561Lysfs | Deletion     | Likely pathogenic | (+) (-) (-) (+) | NA  | (+)                | (+)                        |
| 4        | MLH1                      | NM_000249.3    | Exon 12     | c.1393dupA | p Thr465Asnfs | Insertion     | Likely pathogenic | (-) (+) (+) (-) | MSH | (+)                | (-)                        |
| 5        | MSH2                      | NM_000251.2    | Exon 12     | c.1813delG | p.Val605Leufs | Deletion     | Likely pathogenic | (+) (+) (+) (+) | MSH | (-)                | (-)                        |
| 6        | MSH6                      | NM_000179.2    | Exon 4      | c.2598_2602delAGTAA | p.Lys866Asnfs | Deletion     | Likely pathogenic | (+) (+) (-) (+) | MSH | (-)                | (-)                        |
| 7        | MSH6                      | NM_000179.2    | Exon 4      | c.A1828G   | p.Lys610Glu  | Missense     | Uncertain significance | (+) (+) (+) (+) | MSS | (-)                | (-)                        |
| 8        | PMS2                      | NM_000535.6    | Exon 14     | c.G2438A   | p.Arg813Gln  | Missense     | Uncertain significance | (+) (+) (+) (+) | MSS | (-)                | (-)                        |
| 9        | MSH6                      | NM_000179.2    | Exon 4      | c.C926A    | p.Ser309Ter  | Nonsense     | Pathogenic    | (+) (+) (+) (+) | MSH | (-)                | (-)                        |
| 10       | MSH6                      | NM_000179.2    | Exon 4      | c.C926G    | p.Ser309Cys  | Missense     | Uncertain significance | (+) (+) (+) (+) | MSS | (-)                | (-)                        |
| 11       | MSH2                      | NM_000251.2    | Exon 1      | c.C14A     | p.Pro5Gln    | Missense     | Uncertain significance | (+) (+) (+) (+) | MSS | (-)                | (-)                        |
| 12       | MSH6                      | NM_000179.2    | Exon 4      | c.G1063A   | p.Gly355Ser  | Missense     | Uncertain significance | (+) (+) (+) (+) | MSS | (-)                | (-)                        |
| 13       | MSH6                      | NM_000179.2    | Exon 2      | c.A335G    | p.Asn112Ser  | Missense     | Uncertain significance | (+) (+) (+) (+) | MSS | (-)                | (-)                        |
| 14       | MSH6                      | NM_000179.2    | Exon 5      | c.C3260G   | p.Pro1087Arg | Missense     | Uncertain significance | (+) (+) (+) (+) | MSS | (-)                | (-)                        |
| 15       | MSH6                      | NM_000179.2    | Exon 10     | c.C4051G   | p.His1351Asp | Missense     | Uncertain significance | (+) (+) (+) (+) | MSS | (-)                | (-)                        |
| 16       | MSH6                      | NM_000179.2    | Exon 4      | c.C926G    | p.Ser309Cys  | Missense     | Uncertain significance | (+) (+) (-) (+) | MSH | (-)                | (-)                        |
| 17       | MSH6                      | NM_000179.2    | Exon 4      | c.G1063A   | p.Gly355Ser  | Missense     | Uncertain significance | (-) (+) (+) (-) | MSH | (-)                | (-)                        |
| 18       | MSH6                      | NM_000179.2    | Exon 4      | c.A1828G   | p.Lys610Glu  | Missense     | Uncertain significance | (+) (+) (+) (-) | NA  | (-)                | (-)                        |
| 19       | MSH6                      | NM_000179.2    | Exon 4      | c.A1937G   | p.Lys646Arg  | Missense     | Uncertain significance | (+) (+) (+) (+) | NA  | (-)                | (-)                        |
| 20       | MSH6                      | NM_000251.2    | Exon 1      | c.C114A    | p.Pro5Gln    | Missense     | Uncertain significance | (+) (+) (+) (+) | MSS | (-)                | (-)                        |

MMR: mismatch repair; IHC: immunohistochemistry; MLH1: mutL homolog 1; MSH2: mutS homolog 2; MSH6: mutS homolog 6; MSI: microsatellite instability; PMS2: postmeiotic segregation increased 2 (S. cerevisiae); MSH-H: high-frequency microsatellite instability; MSS: microsatellite stable; NA: not available

* All the mutations are heterozygous variants
Accuracy of the screening methods
The family histories of all 111 patients were evaluated. Due to insufficient tumor tissues for examination, IHC was performed for only 102 (91.9%) patients, and MSI test was performed for 83 (74.8%) patients.

Based on their clinical characteristics, 14 patients (12.6%) were suspected as having LS-EC by the Amsterdam II criteria, and 2 of them also met the revised Bethesda guidelines. All of the 14 patients underwent IHC examination of MMR proteins, and 7 (50.0%) were found to have intact MMR genes; MSI test was performed for 8 of the 14 patients, and identified MSI-H (MLH1 mutation) in 1 patient and MSS in 7 patients. However, NGS revealed that 12 (85.7%) of the 14 patients were misdiagnosed by the clinical criteria, and only 2 (14.3%) were confirmed to have LS-EC. On the other hand, of the 97 patients not suspected as having LS-EC by the clinical criteria, 4 were eventually diagnosed with LS-EC. The sensitivity, specificity, PPV, and NPV of the clinical criteria for identifying LS-EC were 33.3%, 88.6%, 14.3%, and 95.9%, respectively (Table 3).

Among the 102 patients, IHC revealed that 28 (27.5%) were IHC MMR protein-deficient: 14 with both MLH1 and PMS2 protein deletion, 5 with both MSH2 and MSH6 deletion, 3 with MSH6 deletion, 3 with PMS2 deletion, and 1 each with MLH1 deletion, MSH2 deletion, and MLH1 and MSH6 deletion. The IHC MMR protein-deficient group was younger and had more advanced lesions than the IHC MMR protein-intact group, but these differences were not significant (Table 1). The sensitivity, specificity, PPV, and NPV of IHC of MMR proteins for identifying LS-EC were 66.7%, 75.0%, 14.3%, and 97.3%, respectively (Table 3). Among the 15 patients with MLH1 deletion, 3 had no hypermethylation of MLH1 promoter, and only one was confirmed to have LS-EC by NGS (Case 4 in Table 2 and Fig. 2). The 12 patients with MLH1 promoter hypermethylation harbored no deleterious mutations.

MSI test of the 83 patients classified 12 (14.5%) as MSI-H and 71 (85.5%) as MSS. The MSI-positive group had higher gravidity than the MSI-negative group (p = 0.020) (Table 1). The sensitivity, specificity, PPV, and NPV of MSI test for identifying LS-EC were 100%, 89.9%, 33.3%, and 100%, respectively. An example of the MSI analysis is presented in Fig. 3.

There was no significant difference in sensitivity between IHC of MMR proteins and the clinical diagnostic criteria (p = 0.284) or between MSI test and the clinical diagnostic criteria (p = 0.071). For the combination of IHC of MMR proteins and MSI test, the sensitivity, specificity, PPV, and NPV were 100%, 72.4%, 20.0%, and 100%, respectively. Thus, the combination of IHC and MSI test had higher sensitivity than the clinical criteria (p = 0.030).

Concordance between IHC of MMR proteins and MSI
A total of 77 patients had both IHC and MSI results available; 10 of them were MSI-H and MMR protein-deficient, and 63 were MSS and MMR protein-intact. Two patients were MSS and MMR protein-deficient, and 2 were MSI-H and MMR protein-intact. MSI test and

Table 3 Accuracy of clinical diagnostic criteria, IHC of MMR proteins, and MSI test in screening Lynch syndrome-associated endometrial carcinoma

| Screening method | NGS (cases) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|------------------|-------------|----------------|----------------|---------|---------|
|                  | LS-EC       | Non-LS-EC      |                |         |         |
| Total            | 6           | 105            | 33.3           | 88.6    | 14.3    | 95.9    |
| Clinical criteria|             |                |                |         |         |
| Met              | 2           | 12             | 33.3           | 88.6    | 14.3    | 95.9    |
| Unmet            | 4           | 93             | 66.7           | 75.0    | 33.3    | 100     |
| IHC              |             |                |                |         |         |
| MMR-deficient    | 4           | 24             | 100.0          | 89.9    | 33.3    | 100.0   |
| MMR-intact       | 2           | 72             | 100.0          | 89.9    | 33.3    | 100.0   |
| MSI              |             |                |                |         |         |
| Positive         | 4           | 8              | 100.0          | 72.4    | 20.0    | 100.0   |
| Negative         | 0           | 71             | 100.0          | 72.4    | 20.0    | 100.0   |
| IHC plus MSI     |             |                |                |         |         |
| MMR-deficient or MSI-positive | 6 | 24 | 100.0 | 72.4 | 20.0 | 100.0 |
| MMR-intact and MSI-negative | 0 | 63 | 100.0 | 72.4 | 20.0 | 100.0 |

Due to insufficient tumor tissues for examination, IHC was performed for only 102 patients, and MSI test was performed for 83 patients

IHC: immunohistochemistry; MMR: mismatch repair; MSI: microsatellite instability; NGS: next-generation sequencing; LS-EC: Lynch syndrome-associated endometrial carcinoma; NPV: negative predictive value; PPV: positive predictive value
IHC were highly concordant for LS-EC screening (73/77, 94.8%).

**Discussion**

The present study reported the performance of universal screening and validation with NGS for LS in a cohort of surgically staged EC patients in China. In total, LS was confirmed in 6 (5.4%) EC patients by NGS. The prevalence of LS in EC patients is not low, suggesting that selective screening for LS among EC patients is unreasonable. Consistent with the previously reported LS prevalence of 8.5% in EC patients <50 years old [26] and 5.9% in all-age EC patients [27], the present study revealed similar LS prevalence in a Chinese population of EC patients. LS was not diagnosed in any patient over 70 years of age in the present study, which may be related to the low prevalence of LS-EC in the general population and the small sample size of our cohort. However, the reported prevalence of LS-EC varied from 2.1% (21/1002) [19] to 3.9% (7/179) [20] and 6.6% (40/605) [12]. These differences were likely caused by the screening methods and study populations.

Although the protocol for screening EC patients for LS remains a subject of debate [28], the results in the present study suggest that universal molecular screening rather than using clinical criteria is necessary. However, the selection of appropriate methods and strategies is also debatable. Our data suggest that, for LS-EC, the clinical criteria should not be used alone in routine practice because of its low sensitivity and PPV. As over one-third...
of ECs in young women cannot be attributed to excess estrogen or hereditary syndromes [29], clinicopathological factors are not suitable for LS-EC screening [26], although some studies recommended selective screening based on the clinicopathological features because they can be examined inexpensively and noninvasively [30, 31]. There are several reasons that could explain the low PPV of the clinical criteria. MSH6 mutation-associated EC is common in the elderly and patients with no family history of cancer, and the penetrance of PMS2 mutation is lower than that of MLH1 or MSH2 mutation. Therefore, MSH6 and PMS2 mutations are especially likely to be missed in selective screening according to clinical criteria [32, 33]. Approximately 70% of LS patients did not meet the Amsterdam II criteria or revised Bethesda guidelines because the sizes of many families with mutations were too small or the cancer appeared late in life [34]. In addition, these criteria were formulated mainly for colorectal cancer, and EC was not adequately evaluated [32]. Mills et al. [15] reported that 57.1% of patients with LS would not be identified based on age and individual cancer history, and 28.6% would not be identified even with a complete family history. Overall, these problems limit the application of clinical criteria.

Our findings suggest that a combination of IHC of MMR proteins and MSI test for the screening of LS-EC would achieve favorable screening accuracy. This recommendation has been supported by recent reports and guidelines [19, 20, 29, 35, 36]. However, few studies used universal molecular screening and NGS for confirmation, which explained various and even inconsistent prevalence of LS-EC. More importantly, these reports did not include the data of Chinese population. Molecular screening methods had their own limitations. Given the high rate of MSH6 mutations in patients with LS-EC and the low predictive value of MSI in identifying MSH6 mutation-associated LS, IHC, rather than MSI test, has been suggested as the primary screening approach for LS in patients with EC [37]. However, IHC is limited by the high interobserver variability. Making a definitive diagnosis is difficult when the protein expression is weakly positive and heterogeneous [38, 39]. MSI also has disadvantages as a screening tool, such as its high cost and strict criteria for sequencing and interpretation. Indeed, according to the guideline recommendations [21, 35, 40] and the results of the present study, screening with only one method is insufficient, and combination screening is appropriate in the current clinical practice.

As previously reported [36] and observed in the present study, MSI test and IHC were highly concordant for EC screening. The discordant MMR protein-proficient/MSI-H cases (<1%) may be explained by MLH1 promoter hypermethylation or other unknown gene mutations. However, deviations in technique and interpretation may also be partially responsible for this discordance. As our data suggested, hypermethylation is an important indication of conducting NGS in MLH1-negative patients. In the present study, 3 (20.0%) of 15 MLH1-negative patients had no hypermethylation, and 1 of them was confirmed to have LS-EC, which was consistent with previous reports [15, 20].

The current study has some limitations. The significant association between EC risk and family history regardless of proband MMR status and after the exclusion of probands carrying pathogenic MMR variants indicated that MMR genes could not fully explain familial EC risk [41]. Thus, continued research on familial EC is essential. Polygenic interactions have been suggested to be the most likely cause of cancer development in LS patients [42]. Hence, multigene panel test in a large cohort is ongoing at our institute to more definitively determine the prevalence of hereditary EC in China. Additionally, the limited sample size of the present study probably limits the generalizability of our findings. Finally, a cost-effectiveness analysis is lacking due to the limited sample size. In the present study, the costs of molecular screening methods and NGS were much lower than previously reported [20, 43]. A comprehensive analysis of cost-effectiveness would aid in optimizing screening strategies for LS [44, 45]. Routine LS screening in patients ≤70 years of age has been demonstrated to be a cost-effective strategy [20, 46]. Key determinants of whether screening is cost-effective are the accuracy of tumor-based tests, the risk
of cancer without surveillance, the number of relatives identified for cascade test, the effectiveness of colonoscopy surveillance, and patient acceptance of genetic test [47].

Conclusions
Our findings showed that for identifying LS in women presenting with EC, screening with a combination of IHC of MMR proteins and MSI test was superior to the clinical criteria alone. MSI test and IHC were found to be highly concordant for EC screening. Although only six cases of LS-EC were identified in the present study, universal screening and validation in unselected patients would provide substantial evidence to inform clinical decision making between patients and physicians.

Abbreviations
LS: Lynch syndrome; DNA: deoxyribonucleic acid; MMR: mismatch repair; LS-EC: LS-associated endometrial carcinoma; EC: endometrial carcinoma; MLH1: Mut. homolog 1; MSH2: MutS homolog 2; MSH6: MutS homolog 6; PMS2: PMS1 homolog 2; EPCAM: epithelial cell adhesion molecule; NCCN: National Comprehensive Cancer Network; IHC: immunohistochemical; MSI: microsatellite instability; AGO: Arbeitsgemeinschaft für Gynäkologische Onkologie (Australia); CAMS: Chinese Academy of Medical Sciences; MS-MLPA: methylation-specific multiplex ligation-dependent probe amplification; PCR: polymerase chain reaction; MSI-H: high-frequency MSI; MSI-L: low-frequency MSI; MSS: microsatellite stable; TILLING: PCR amplifier sequence; qPCR: quantitative polymerase chain reaction; SNPs: single-nucleotide polymorphisms; ACMG: American College for Medical Genetics and Genomics; NGS: next-generation sequencing; SSPT: Statistical Product and Service Solutions; SDs: standard deviations; FIGO: International Federation of Gynecology and Obstetrics; BMI: body mass index; PPV: positive predictive value; NPV: negative predictive value.

Acknowledgements
We thank Springer Nature for professional editing services.

Authors’ contributions
XC was responsible for the statistical analysis and manuscript preparation; LL was responsible for the study concepts, design, data acquisition, quality control of data and algorithms, and manuscript editing and review. YB, MW, SM, and SJ were all responsible for the data acquisition and manuscript review. JL was responsible for the study design and the data analysis and interpretation. YB was responsible for the pathological evaluation. All authors read and approved the final manuscript.

Funding
This study was supported by the Chinese Academy of Medical Sciences Initiative for Innovative Medicine (CAMS-2017-12M-1-002) and by the National Science-technology Support Plan Projects (2015BAI13B04). The funders had no role in the study design, the data collection and analysis, the decision to publish, or the preparation of the manuscript.

Availability of data and materials
The datasets used in this study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The Institutional Review Board of Peking Union Medical College Hospital approved this study (No. JS-1370) under registration No. NCT03291106 (clinicaltrials.gov). All patients had given consent before enrollment.

Consent for publication
The study participants provided written consent for the publication of this information.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Shuaifuyuan No. 1, Dongcheng District, Beijing 100730, PR. China. 2 Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing 100730, PR. China.

Received: 1 February 2019 Accepted: 10 July 2019 Published online: 15 July 2019

References
1. Moller P, Seppala TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch syndrome database. Gut. 2018;67(1):106–16.
2. Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17(1):70–87.
3. BoileSEN AE, Bisgaard ML, Bernstein I. Risk of gynecologic cancers in Danish hereditary non-polyposis colorectal cancer families. Acta Obstet Gynecol Scand. 2008;87(11):1129–35.
4. Watson P, VaseN HFA, Mecklin JP, Bernstein I, Aarnio M, Jarvinen HJ, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008;123(2):444–9.
5. Tale LJ, Riggs ER, Tsongalis GJ. Lynch syndrome presenting as endometrial cancer. Clin Chem. 2014;60(1):111–21.
6. Wang Y, Li J, Cragun J, Hatch K, Chambers SK, Zheng W. Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium. J Hematol Oncol. 2013;6:22.
7. Moller P, Seppala T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopy and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. 2017;66(3):464–72.
8. Lynch HT, Boland CR, Gong G, Shaw TG, Lynch PM, Fodde R, et al. Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet. 2006;14(4):390–402.
9. Sinicrope FA. Lynch syndrome—associated colorectal cancer. N Engl J Med. 2018;379(8):764–73.
10. Hampel H, Pearlman R, Beigthol M, Zhao W, Jones D, Frankel WL, et al. Assessment of tumor sequencing as a replacement for Lynch syndrome screening and current molecular tests for patients with colorectal cancer. JAMA Oncol. 2018;4:806–13.
11. Clarke BA, Cooper K. Identifying Lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas. Adv Anat Pathol. 2012;19(4):231–8.
12. Mills AM, Liu S, Foro JD, Berek JS, Pai RK, Longace TA. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol. 2014;38(11):1501–9.
13. VaseN HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPPC, Lynch syndrome) proposed by the International Collaborative group on HNPPC. Gastroenterology. 1999;116(6):1453–6.
14. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.
15. Mills AM, Sloan EA, Thomas M, Modissett SC, Stoler MH, Atkins KA, et al. Clinicopathologic comparison of Lynch syndrome-associated and “Lynch-like” endometrial carcinomas identified on universal screening.
using mismatch repair protein immunohistochemistry. Am J Surg Pathol. 2016;40(2):155–65.

16. Ryan P, Mulligan AM, Aronson M, Ferguson SE, Bapat B, Semotuk K, et al. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer. 2012;118(3):681–8.

17. Qian CN. At-home cancer screening: a solution for China and other developing countries with a large population and limited number of healthcare practitioners. Chin J Cancer. 2017;36(1):68.

18. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Uterine neoplasms. Version 1. 2019. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Accessed 15 Jan 2019.

19. Goodfellow PJ, Billingsley CC, Lankes HA, Ali S, Cohn DE, Broadus RJ, et al. Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for Lynch syndrome screening in endometrial cancers from GOG210, an NRG Oncology and Gynecologic Oncology Group Study. J Clin Oncol. 2015;33(36):4001–8.

20. GoveAde R, Spaan d er MC, van Doorn HC, Dub bink HJ, van den Ouweland AM, Tops CM, et al. Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70 years of age. Gynecol Oncol. 2016;143(3):453–9.

21. Zeimet AG, Mori H, Petru E, Poltersauer S, Reinthaller A, Schauer C, et al. ACOG Austria recommendation on screening and diagnosis of Lynch syndrome (LS). Arch Gynec Obstet. 2017;296(1):123–7.

22. Zhou JY, Zhang L, Wei LH, Wang J. Endometrial carcinoma-related genetic factors: application to research and clinical practice in China. BJOG. 2016;123(Suppl 3):90–6.

23. van Lier MG, Wagner A, van Leer dam ME, Biermann K, Kuipers EJ, van Leerdam ME, et al. Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for Lynch syndrome screening in endometrial cancers. Obstet Gynecol. 2014;120(24):3932–9.

24. Talseth-Palmer BA, Bauer DC, Sjursen W, Evans TJ, McPhillips M, Proietto A, et al. Targeted next-generation sequencing of 22 mismatch repair genes independently of Lynch syndrome: implications for genetic counselling. Gynecol Oncol. 2017;147(2):381–7.

25. Resnick KE, Hampel H, Fishel R, Cohn DE. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol. 2009;114(1):128–34.

26. Shia J, Holick S, De petris G, Green w on JK, Klimstra DS. Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry. Fam Cancer. 2013;12(2):241–60.

27. Kato A, Sato N, Sugawara T, Takahashi K, Kito M, Makino K, et al. Isolated loss of MLH1 immunohistochemical expression is frequently caused by heterogenous MLH1 promoter hypermethylation in Lynch syndrome. J Clin Oncol. 2017;35(19):2179–86.

28. Vasen HF, Blanco I, Ak tan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62(6):812–23.

29. Johntty SE, Tan YF, Buchanan DD, Bowman M, Walters RJ, Obermair A, et al. Family history of cancer predicts endometrial cancer risk independently of Lynch syndrome: implications for genetic counselling. Gynecol Oncol. 2017;147(2):381–7.

30. Talseth-Palmer BA, Bauer DC, Si jursen W, Evans TJ, McPhillips M, Proietto A, et al. Targeted next-generation sequencing of 22 mismatch repair genes identifies Lynch syndrome fam ilies. Cancer Med. 2016;5(5):929–41.

31. Usha L, Dewdney SB, Buckingham LE. Tumor screening and DNA testing in Lynch syndrome patients up to 70 years of age. Gynecol Oncol. 2009;114(1):128–34.

32. Mol ine J, Eng C. Equality in Lynch syndrome screening: why should we hold patients with endometrial cancer to a different standard? J Clin Oncol. 2014;32(21):2277.

33. Cohen SA, Leininger A. The genetic basis of Lynch syndrome and its implications for clinical practice and risk management. Appl Clin Genet. 2014;7:147–58.

34. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-risk Assessment: Colorectal. Version 1. 2018. https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf. Accessed 12 July 2018.

35. Batte BA, Bruegl AS, Daniels MS, Ring KL, Dempsey KM, Djordjevic B, et al. Consequences of universal MSI/H+IC in screening endometrial cancer patients for Lynch syndrome. Gynecol Oncol. 2014;134(2):319–25.

36. Mol ine J, Eng C. Equality in Lynch syndrome screening: why should we hold patients with endometrial cancer to a different standard? J Clin Oncol. 2014;32(21):2277.

37. Mol ine J, Eng C. Equality in Lynch syndrome screening: why should we hold patients with endometrial cancer to a different standard? J Clin Oncol. 2014;32(21):2277.

38. Mol ine J, Eng C. Equality in Lynch syndrome screening: why should we hold patients with endometrial cancer to a different standard? J Clin Oncol. 2014;32(21):2277.

39. Mol ine J, Eng C. Equality in Lynch syndrome screening: why should we hold patients with endometrial cancer to a different standard? J Clin Oncol. 2014;32(21):2277.